help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holte, J.
Right arrow Articles by Berne, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holte, J.
Right arrow Articles by Berne, C.
The Journal of Clinical Endocrinology & Metabolism Vol. 83, No. 4 1143-1150
Copyright © 1998 by The Endocrine Society


Original Articles

High Prevalence of Polycystic Ovaries and Associated Clinical, Endocrine, and Metabolic Features in Women with Previous Gestational Diabetes Mellitus

Jan Holte, Gianluca Gennarelli, Leif Wide, Hans Lithell and Christian Berne

Departments of Obstetrics and Gynecology (J.H., G.G.), Clinical Chemistry (L.W.), Geriatrics (H.L.), and Internal Medicine (C.B.), Uppsala University, S-751 85 Uppsala, Sweden

Address all correspondence and requests for reprints to: Dr. Jan Holte, Department of Obstetrics and Gynecology, Akademiska Hospital, Uppsala University, S-751 85 Uppsala, Sweden.

Abstract

The prevalence of polycystic ovaries, according to ultrasonography, and associated clinical, endocrine, and metabolic features were investigated in women with previous gestational diabetes mellitus (GDM). Thirty-four women with GDM 3–5 yr before the investigation and 36 controls with uncomplicated pregnancies, selected for similar age, parity, and date of delivery, were investigated. The women with previous GDM showed a higher prevalence of polycystic ovaries [14 of 34 (41%) vs. 1 of 36 (3%); P < 0.0001], hirsutism (P < 0.01), irregular menstrual cycles (P < 0.01), and a higher body mass index (BMI; P < 0.001) than the controls. Five women (15%) with previous GDM had developed manifest diabetes (excluded in comparisons of metabolic variables). After dividing the women with previous GDM into subgroups according to ovarian appearance, the 2 subgroups showed similar glucose tolerance and prevalence of diabetes, whereas the women with polycystic ovaries were younger (mean ± SD, 33.3 ± 1.4 vs. 38.2 ± 1.1; P < 0.01), had higher truncal-abdominal/femoral fat ratio according to skin folds (P < 0.05), had higher concentrations of androstenedione (P < 0.01) and testosterone (P < 0.01), and had a higher LH/FSH ratio (P < 0.01), lower levels of GH (P < 0.01), higher levels of triglycerides (P < 0.05) and cholesterol (P < 0.05) in very low density lipoprotein, all independent of age and BMI, and had a higher prevalence of pregnancy-induced hypertension (50% vs. 15%; P < 0.05) during the index pregnancy compared with the women with normal ovaries.

The group of women with GDM showed a lower early insulin release after glucose (iv glucose tolerance test) for their degree of insulin resistance (euglycemic hyperinsulinemic clamp) compared with controls (P < 0.05). In the two subgroups, insulin sensitivity was lower in the polycystic ovaries group, independent of BMI (P < 0.05), than in the group with normal ovaries.

In conclusion, ultrasonographic, clinical and endocrine signs of polycystic ovary syndrome were much increased in women with a history of GDM. Compared with the women with normal ovaries and previous GDM, those with polycystic ovaries formed a distinct subgroup that may be more prone to develop various features of the insulin resistance syndrome. Both groups showed a similarly disturbed balance between ß-cell activity and insulin sensitivity, but in women with polycystic ovaries, insulin resistance may be the dominant component.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
K. E. S. Salley, E. P. Wickham, K. I. Cheang, P. A. Essah, N. W. Karjane, and J. E. Nestler
POSITION STATEMENT: Glucose Intolerance in Polycystic Ovary Syndrome A Position Statement of the Androgen Excess Society
J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4546 - 4556.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
B. Trolle, A. Flyvbjerg, U. Kesmodel, and F.F. Lauszus
Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial
Hum. Reprod., November 1, 2007; 22(11): 2967 - 2973.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
R. S. Legro
A 27-Year-Old Woman With a Diagnosis of Polycystic Ovary Syndrome
JAMA, February 7, 2007; 297(5): 509 - 519.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
B. Banaszewska, L. Pawelczyk, R. Z. Spaczynski, J. Dziura, and A. J. Duleba
Effects of Simvastatin and Oral Contraceptive Agent on Polycystic Ovary Syndrome: Prospective, Randomized, Crossover Trial
J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 456 - 461.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
R. PASQUALI and A. GAMBINERI
Polycystic Ovary Syndrome: A Multifaceted Disease from Adolescence to Adult Age
Ann. N.Y. Acad. Sci., December 1, 2006; 1092(1): 158 - 174.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
J. C. Lo, S. L. Feigenbaum, G. J. Escobar, J. Yang, Y. M. Crites, and A. Ferrara
Increased Prevalence of Gestational Diabetes Mellitus Among Women With Diagnosed Polycystic Ovary Syndrome: A population-based study
Diabetes Care, August 1, 2006; 29(8): 1915 - 1917.
[Full Text] [PDF]


Home page
Eur J EndocrinolHome page
R. Pasquali and A. Gambineri
Insulin-sensitizing agents in polycystic ovary syndrome.
Eur. J. Endocrinol., June 1, 2006; 154(6): 763 - 775.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. M. Heitritter, C. G. Solomon, G. F. Mitchell, N. Skali-Ounis, and E. W. Seely
Subclinical Inflammation and Vascular Dysfunction in Women with Previous Gestational Diabetes Mellitus
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3983 - 3988.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
M.A. Checa, A. Requena, C. Salvador, R. Tur, J. Callejo, J.J. Espinos, F. Fabregues, J. Herrero, and (Reproductive Endocrinology Interest Group of the
Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome
Hum. Reprod. Update, July 1, 2005; 11(4): 375 - 390.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. O. Goodarzi, S. Erickson, S. C. Port, R. I. Jennrich, and S. G. Korenman
{beta}-Cell Function: A Key Pathological Determinant in Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 310 - 315.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
A. Gambineri, C. Pelusi, E. Manicardi, V. Vicennati, M. Cacciari, A. M. Morselli-Labate, U. Pagotto, and R. Pasquali
Glucose Intolerance in a Large Cohort of Mediterranean Women With Polycystic Ovary Syndrome: Phenotype and Associated Factors
Diabetes, September 1, 2004; 53(9): 2353 - 2358.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
R. S. Legro, E. Myers, and for the Reproductive Medicine Network
Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome?
Hum. Reprod., August 1, 2004; 19(8): 1697 - 1704.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
V. De Leo, A. la Marca, and F. Petraglia
Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome
Endocr. Rev., October 1, 2003; 24(5): 633 - 667.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Diamanti-Kandarakis, J.-P. Baillargeon, M. J. Iuorno, D. J. Jakubowicz, and J. E. Nestler
A Modern Medical Quandary: Polycystic Ovary Syndrome, Insulin Resistance, and Oral Contraceptive Pills
J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1927 - 1932.
[Full Text] [PDF]


Home page
Hum ReprodHome page
J. E. Nestler
Should patients with polycystic ovarian syndrome be treated with metformin?: An enthusiastic endorsement
Hum. Reprod., August 1, 2002; 17(8): 1950 - 1953.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
R. J. Norman, L. Masters, C. R. Milner, J. X. Wang, and M. J. Davies
Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome
Hum. Reprod., September 1, 2001; 16(9): 1995 - 1998.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. M. Koivunen, J. Juutinen, I. Vauhkonen, L. C. Morin-Papunen, A. Ruokonen, and J. S. Tapanainen
Metabolic and Steroidogenic Alterations Related to Increased Frequency of Polycystic Ovaries in Women with a History of Gestational Diabetes
J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2591 - 2599.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. Mikola, V. Hiilesmaa, M. Halttunen, L. Suhonen, and A. Tiitinen
Obstetric outcome in women with polycystic ovarian syndrome
Hum. Reprod., February 1, 2001; 16(2): 226 - 229.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
Polycystic Ovary Syndrome, Gestational Diabetes, and Bulimia Nervosa
J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4746 - 4746.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1998 by The Endocrine Society